Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
Open accessThe DOI matches its Crossref record; 188 of the 191 references it cites were found in a registry or an index.
Abstract
Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA)A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some of which differ significantly. The conventional BZDs clonazepam, diazepam, lorazepam and midazolam differ mainly in their durations of action and available routes of administration. In addition to the common intravenous, intramuscular and rectal administrations that have long been established in the acute treatment of SE, other administration routes for BZDs—such as intranasal administration—have been developed in recent years, with some preparations already commercially available. Most recently, the intrapulmonary administration of BZDs via an inhaler has been investigated. This narrative review provides an overview of the current knowledge on the efficacy and tolerability of different BZDs, with a focus on different routes of administration and therapeutic specificities for different patient groups, and offers an outlook on potential future drug developments for the treatment of prolonged seizures and SE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Mean time from drug administration to cessation of status epilepticus (SE) in minutes is displayed for different delivery routes, based on literature research, as far as available (n.a. = not available). Intravenous (i.v.) administration showed the fastest onset of action with a latency of less than 3 min, followed by intranasal (i.n.) and intramuscular (i.m.) administration, as well as buccal and rectal delivery. Due to the heterogeneous patient populations and study settings, the displayed values should only serve as a basic guidance [48, 50, 51, 146, 186–190]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/7b44ab2840314fb286af9f300a0a85a9/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-2.jpg)
![Fig. 3 Time from therapy administration to cessation of status epilepticus (SE) is displayed to help decide on the clinical use of different delivery routes for benzodiazepines in SE, based on published preparations and process times for drug administration via intravenous injection (i.v.), intramuscular injection (i.m.), rectal, intranasal (i.n.) and buccal administration [48]. For i.v. administration, it was assumed that no peripheral indwelling venous catheter had yet been established analogous to Silbergleit et al. [48]. MDZ midazolam, LZP lorazepam, DZP diazepam, CZP clonazepam](https://figures.cochat.ai/paper-figures/9a5a8394f39342a6908fa83a02f2e299/benzodiazepines-in-the-management-of-seizures-and-status-epilepticus-a-review-of-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pre-hospital benzodiazepine administration may be effective in controlling repetitive seizures or status epilepticus and avoid hospitalization 212,213 .”
From Developmental and epileptic encephalopathies (2024) · cites this paper as [212]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Long-term BZD use may also be appropriate for medical conditions such as complex seizure disorders,42 spasticity,43,44 sleep disorders involving abnormal movements (e.g., rapid eye movement (REM) sleep behavior disorder, restless leg syndrome),45 and catatonia.46,47”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 3×
“Typically, the start of SE treatment is based on t1, with the time limit being 5 min for generalized convulsive (tonic–clonic) SE, 10 min for complex focal SE (focal SE with impaired consciousness), and 10–15 min for absence SE [16].”
BackgroundA Comparison of Four Treatments for Generalized Convulsive Status Epilepticus
Treiman, D. M., Meyers, P. D., Walton, N. Y., Collins, J. F., Colling, C., Rowan, A. J., Handforth, A., Faught, E., Calabrese, V. P., Uthman, B. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391202 · Cited by 1,325 · cited 1×
“[47] in 1988, which demonstrated a superior efficacy of LZP over phenobarbital (PB) and at least equal efficacy to phenytoin (PHT ± DZP) as a first-line treatment for SE.”
BackgroundGlauser, T., Shinnar, S., Gloss, D., Alldredge, B., Arya, R., Bainbridge, J., Bare, M., Bleck, T., Dodson, W. E., Garrity, L., et al. (2016) · Epilepsy Currents · doi:10.5698/1535-7597-16.1.48 · Cited by 1,280 · cited 5×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
BackgroundInfluentialAlldredge, B. K., Gelb, A. M., Isaacs, S. M., Corry, M. D., Allen, F., Ulrich, S., Gottwald, M. D., O'Neil, N., Neuhaus, J. M., Segal, M. R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002141 · Cited by 888 · cited 2×
“[22] conducted a large placebo-controlled trial, showing that LZP at a dose of 2 mg led to seizure termination more frequently than placebo or DZP following i.”
BackgroundMethodIt’s time to revise the definition of status epilepticus
Lowenstein, D. H., Bleck, T., & Macdonald, R. L. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02000.x · Cited by 805 · cited 1×
“The 5-min time limit that usually marks the transition from a prolonged seizure to SE dates back to an operational definition proposed by Lowenstein in 1999, aimed at ensuring that patients receive treatment as soon as possible [17].”
BackgroundIntramuscular versus Intravenous Therapy for Prehospital Status Epilepticus
Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., & Barsan, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107494 · Cited by 744 · cited 3×
“LZP showed a similar rate of seizure cessation [52]; albeit, this particular randomized trial was underpowered and was based on a re-analysis of [48].”
BackgroundResultInfluentialClinical Pharmacokinetics of Diazepam
Mandelli, M., Tognoni, G., & Garattini, S. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803010-00005 · Cited by 496 · cited 1×
“The half-life of DZP is 24–48 h due to an extended redistribution into the muscle and fat tissue after initial adsorption [90].”
BackgroundBetjemann, J. P., & Lowenstein, D. H. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00042-3 · Cited by 495
McIntyre, J., Robertson, S., Norris, E., Appleton, R., Whitehouse, W. P., Phillips, B., Martland, T., Berry, K., Collier, J., Smith, S., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66909-7 · Cited by 445 · cited 2×
“3 mg/kg) with regard to response rate (cessation of seizures) in paediatric patients in randomized, controlled trials [12, 75].”
BackgroundEFNS guideline on the management of status epilepticus in adults
Meierkord, H., Boon, P., Engelsen, B., Göcke, K., Shorvon, S., Tinuper, P., & Holtkamp, M. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02917.x · Cited by 433 · cited 1×
“Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140].”
BackgroundKapur, J., & Macdonald, R. L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07532.1997 · Cited by 427 · cited 2×
“access may lead to a delay in drug administration, rendering the development of alternative suitable routes vital, as responsiveness to BZDs during seizures decays over time [11].”
BackgroundStatus epilepticus at an urban public hospital in the 1980s
Lowenstein, D. H., & Alldredge, B. K. (1993) · Neurology · doi:10.1212/wnl.43.3_part_1.483 · Cited by 427
Scott, R. C., Besag, F. M., & Neville, B. G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06425-3 · Cited by 393 · cited 2×
“3 mg/kg) with regard to response rate (cessation of seizures) in paediatric patients in randomized, controlled trials [12, 75].”
BackgroundClinical Pharmacokinetics of Oxazepam and Lorazepam
Greenblatt, D. J. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106020-00001 · Cited by 367 · cited 1×
“Hepatic one-step, non-oxidative conjugation at the 3-hydroxy group to LZP-glucuronide is rapid, after which this non-active metabolite is predominantly excreted renally [42].”
BackgroundDouble-blind study of lorazepam and diazepam in status epilepticus
Leppik, L. E. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330350028021 · Cited by 354 · cited 2×
“use of DZP to LZP or MDZ revealed a SE cessation rate of 72–100% [46, 50, 51, 118, 119].”
MethodResultMidazolam: A review of therapeutic uses and toxicity
Nordt, S. P., & Clark, R. F. (1997) · The Journal of Emergency Medicine · doi:10.1016/s0736-4679(97)00022-x · Cited by 337 · cited 1×
“This drug exhibits anticonvulsant, sedative-hypnotic, anxiolytic, muscle relaxant and amnesic properties [54].”
BackgroundClinical Pharmacology of Midazolam in Infants and Children
Blumer, J. L. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835010-00003 · Cited by 313
Lahat, E. (2000) · BMJ · doi:10.1136/bmj.321.7253.83 · Cited by 294 · cited 1×
“DZP in prolonged (febrile) seizures in children [15, 82].”
BackgroundA comparison of rectal diazepam gel and placebo for acute repetitive seizures
Dreifuss, F. E., Rosman, N. P., Cloyd, J. C., Pellock, J. M., Kuzniecky, R. I., Lo, W. D., Matsuo, F., Sharp, G. B., Conry, J. A., Bergen, D. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806253382602 · Cited by 287 · cited 1×
“Previous studies looking into acute treatment (with DZP) defined them as a characteristic episode of multiple complex partial or generalized convulsive seizures occurring within a 24-h period in adults or a 12-h period in children, with a pattern distinguishable from the patient’s usual seizure pattern, and with an on…”
BackgroundClassics in Chemical Neuroscience: Diazepam (Valium)
Calcaterra, N. E., & Barrow, J. C. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000056 · Cited by 281 · cited 1×
“In addition, it is commonly used off-label for numerous other conditions including insomnia, restless legs syndrome, and pre-/post-operative sedation [86].”
BackgroundPharmacokinetic Optimisation of Benzodiazepine Therapy for Acute Seizures: Focus on Delivery Routes
Rey, E., Tr??luyer, J.-M., & Pons, G. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936060-00003 · Cited by 265
Chin, R. F., Neville, B. G., Peckham, C., Wade, A., Bedford, H., & Scott, R. C. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70141-8 · Cited by 237
Propofol and Midazolam in the Treatment of Refractory Status Epilepticus
Prasad, A., Worrall, B. B., Bertram, E. H., & Bleck, T. P. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.27500.x · Cited by 223
Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat.
Klotz, U., Antonin, K. H., & Bieck, P. R. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30657-9 · Cited by 211
Pharmacotherapy for Status Epilepticus
Trinka, E., Höfler, J., Leitinger, M., & Brigo, F. (2015) · Drugs · doi:10.1007/s40265-015-0454-2 · Cited by 208 · cited 1×
“Here, the comparably long half-life of DZP especially stands out [181].”
BackgroundShaner, D. M., McCurdy, S. A., Herring, M. O., & Gabor, A. J. (1988) · Neurology · doi:10.1212/wnl.38.2.202 · Cited by 207
A Review of Alprazolam Use, Misuse, and Withdrawal
Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000350 · Cited by 195
LORAZEPAM VERSUS DIAZEPAM IN THE ACUTE TREATMENT OF EPILEPTIC SEIZURES AND STATUS EPILEPTICUS
Appletan, R., Sweeney, A., Choonara, I., Robson, J., & Molyneux, E. (1995) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1995.tb15014.x · Cited by 194
Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. H., & Rosenow, F. (2017) · Epilepsia · doi:10.1111/epi.13837 · Cited by 192
Self-citationChildren versus adults: pharmacokinetic and adverse-effect differences
Anderson, G. D. (2002) · Epilepsia · doi:10.1046/j.1528-1157.43.s.3.5.x · Cited by 187
CHAMBERLAIN, J. M., ALTIERI, M. A., FUTTERMAN, C., YOUNG, G. M., OCHSENSCHLAGER, D. W., & WAISMAN, Y. (1997) · Pediatric Emergency Care · doi:10.1097/00006565-199704000-00002 · Cited by 175 · cited 3×
“DZP, respectively [72, 123, 124], and a 94% rate for the r.”
BackgroundLorazepam vs Diazepam for Pediatric Status Epilepticus: A Randomized Clinical Trial
Chamberlain, J. M., Okada, P., Holsti, M., Mahajan, P., Brown, K. M., Vance, C., Gonzalez, V., Lichenstein, R., Stanley, R., Brousseau, D. C., et al. (2014) · JAMA · doi:10.1001/jama.2014.2625 · Cited by 175
Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children
Mahmoudian, T., & Mohammadi Zadeh, M. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.01.003 · Cited by 171
Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo
Greenblatt, D. J., Ehrenberg, B. L., Gunderman, J., Locniskar, A., Scavone, J. M., Harmatz, J. S., & Shader, R. I. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.41 · Cited by 168
Mpimbaza, A., Ndeezi, G., Staedke, S. G., Rosenthal, P. J., & Byarugaba, J. S. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0930 · Cited by 158
Knoester, P. D., Jonker, D. M., van der Hoeven, R. T. M., Vermeij, T. A. C., Edelbroek, P. M., Brekelmans, G. J. F., & de Haan, G. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01588.x · Cited by 157 · cited 1×
“MDZ reaches dose-dependent maximal plasma concentrations after ~ 8–14 min, with sneezing and local irritation reported as the most common side effects [58, 78].”
BackgroundHolsti, M., Dudley, N., Schunk, J., Adelgais, K., Greenberg, R., Olsen, C., Healy, A., Firth, S., & Filloux, F. (2010) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2010.130 · Cited by 154
Intranasal midazolam vs rectal diazepam in acute childhood seizures
Bhattacharyya, M., Kalra, V., & Gulati, S. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.09.006 · Cited by 152 · cited 1×
“With regard to the safety and tolerability of DZP, frequent substance-specific treatment-emergent adverse events (TEAEs) have been identified, including somnolence, sedation, drowsiness, vomiting, hyperactivity, tiredness, hypotension and ataxia [77, 83, 107, 113, 120, 124, 135].”
BackgroundKellinghaus, C., Rossetti, A. O., Trinka, E., Lang, N., May, T. W., Unterberger, I., Rüegg, S. J., Sutter, R., Strzelczyk, A., Tilz, C., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25416 · Cited by 150
Self-citationFişgin, T., Gurer, Y., Tezic, T., Senbil, N., Zorlu, P., Okuyaz, C., & Akgün, D. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700206 · Cited by 138
Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study
Misra, U. K., Kalita, J., & Maurya, P. K. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6227-2 · Cited by 137
Navarro, V., Dagron, C., Elie, C., Lamhaut, L., Demeret, S., Urien, S., An, K., Bolgert, F., Tréluyer, J., Baulac, M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00296-3 · Cited by 137 · cited 2×
“Convulsions stopped after 15 min in 84% (57/68) of patients receiving CZP alone [143].”
BackgroundNeligan, A., Noyce, A. J., Gosavi, T. D., Shorvon, S. D., Köhler, S., & Walker, M. C. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1268 · Cited by 136
Seizure clusters: characteristics and treatment
Haut, S. R. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000177 · Cited by 134 · cited 2×
“The clustering of seizures in turn is a common clinical phenomenon and describes an increase in seizure frequency during a specific period of time, where the probability of seizure occurrence is affected by the occurrence of a previous seizure [26].”
BackgroundOccurrence of seizure clusters and status epilepticus during inpatient video-EEG monitoring
Rose, A., McCabe, P. H., Gilliam, F. G., Smith, B. J., Boggs, J. G., Ficker, D. M., Moore, J. L., Passaro, E. A., & Bazil, C. W. (2003) · Neurology · doi:10.1212/01.wnl.0000053748.83309.28 · Cited by 134
Continuous Midazolam Versus Diazepam Infusion for Refractory Convulsive Status Epilepticus
Singhi, S., Murthy, A., Singhi, P., & Jayashree, M. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700203 · Cited by 134 · cited 2×
“use of DZP to LZP or MDZ revealed a SE cessation rate of 72–100% [46, 50, 51, 118, 119].”
BackgroundMethodGreenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710227 · Cited by 134 · cited 1×
“The duration of action is about 10–20 h and the elimination half-life is 8–25 h [39, 40].”
BackgroundBuccal Absorption of Midazolam: Pharmacokinetics and EEG Pharmacodynamics
Scott, R. C., Besag, F. M. C., Boyd, S. G., Berry, D., & Neville, B. G. R. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01375.x · Cited by 126 · cited 1×
“and buccal routes [12], making it difficult to minimize variability in pharmacodynamics due to variable intake [13].”
BackgroundTreating repetitive seizures with a rectal diazepam formulation: A randomized study
Cereghino, J. J., Mitchell, W. G., Murphy, J., Kriel, R. L., Rosenfeld, W. E., Trevathan, E., & The North American Diastat Study Group* (1998) · Neurology · doi:10.1212/wnl.51.5.1274 · Cited by 119 · cited 1×
“Previous studies looking into acute treatment (with DZP) defined them as a characteristic episode of multiple complex partial or generalized convulsive seizures occurring within a 24-h period in adults or a 12-h period in children, with a pattern distinguishable from the patient’s usual seizure pattern, and with an on…”
BackgroundPharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
Smith, R. B., Kroboth, P. D., VanderLugt, J. T., Phillips, J. P., & Juhl, R. P. (1984) · Psychopharmacology · doi:10.1007/bf00431449 · Cited by 117 · cited 1×
“Alprazolam has an intermediate onset of action (function of rate of absorption) compared to other BZDs and mean plasma elimination half-life of ~6–15 h [169, 170].”
BackgroundDiazepam elimination in premature and full term infants, and children
Morselli, P. L., Principi, N., Tognoni, G., Reali, E., Belvedere, G., Standen, S. M., & Sereni, F. (1973) · Journal of Perinatal Medicine · doi:10.1515/jpme.1973.1.2.133 · Cited by 116 · cited 1×
“DZP has a long half-life in neonates and should be avoided until hepatic metabolic pathways have matured at the age of approximately 6 months [173].”
BackgroundWermeling, D. P. H., Miller, J. L., Archer, S. M., Manaligod, J. M., & Rudy, A. C. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012779 · Cited by 112
Pinder (1976) · doi:10.2165/00003495-197612050-00001 · Cited by 111
Ahmad, S., Ellis, J. C., Kamwendo, H., & MOLYNEUX, E. M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68696-0 · Cited by 111
Mehta, V., SINGHI, P. D., & Singhi, S. C. (2007) · Journal of Child Neurology · doi:10.1177/0883073807306248 · Cited by 105 · cited 2×
“Subsequently, several studies have compared the efficacy of DZP and valproate (VPA) for terminating SE and showed a response rate of 56–85% for DZP and 50–80% for VPA [116, 117].”
BackgroundDetyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.15159 · Cited by 105
Alvarez, V., Lee, J. W., Drislane, F. W., Westover, M. B., Nový, J., Dworetzky, B. A., & Rossetti, A. O. (2015) · Epilepsia · doi:10.1111/epi.13056 · Cited by 101
Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam.
Greenblatt, D. J., Ehrenberg, B. L., Gunderman, J., Scavone, J. M., Tai, N. T., Harmatz, J. S., & Shader, R. I. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21328-3 · Cited by 98
Patterns of benzodiazepine underdosing in the Established Status Epilepticus Treatment Trial
Sathe, A. G., Underwood, E., Coles, L. D., Elm, J., Silbergleit, R., Chamberlain, J. M., Kapur, J., Cock, H. R., Fountain, N. B., Shinnar, S., et al. (2021) · Epilepsia · doi:10.1111/epi.16825 · Cited by 96
De Haan, G., Van Der Geest, P., Doelman, G., Bertram, E., & Edelbroek, P. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2009.02333.x · Cited by 95
Pharmacokinetics and Clinical Use of Benzodiazepines in the Management of Status Epilepticus
Treiman, D. M. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05824.x · Cited by 93
Lorazepam in status epilepticus
Walker, J. E., Homan, R. W., Vasko, M. R., Crawford, I. L., Bell, R. D., & Tasker, W. G. (1979) · Annals of Neurology · doi:10.1002/ana.410060305 · Cited by 90 · cited 1×
“[45] performed a non-randomized prospective trial in patients with SE, resulting in a seizure control rate of 88%.”
MethodAmeer, B., & Greenblatt, D. J. (1981) · Drugs · doi:10.2165/00003495-198121030-00001 · Cited by 88
Lorazepam in childhood status epilepticus and serial seizures: Effectiveness and tachyphylaxis
Crawford, T. O., Mitchell, W. G., & Snodgrass, S. R. (1987) · Neurology · doi:10.1212/wnl.37.2.190 · Cited by 88
Current oral and non-oral routes of antiepileptic drug delivery
Anderson, G. D., & Saneto, R. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.017 · Cited by 88 · cited 1×
“Intramuscular injections can also be challenging in patients with tonic–clonic or hypermotor seizures [7].”
BackgroundArya, R., Gulati, S., Kabra, M., Sahu, J. K., & Kalra, V. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02949.x · Cited by 86 · cited 1×
“There is some evidence that it might be efficacious in SE termination, at least in children [43].”
BackgroundPrediction of Long-term Survival After Status Epilepticus Using the ACD Score
Roberg, L. E., Monsson, O., Kristensen, S. B., Dahl, S. M., Ulvin, L. B., Heuser, K., Taubøll, E., Strzelczyk, A., Knake, S., Bechert, L., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0609 · Cited by 86
Self-citationTreatment of Status Epilepticus with a new Benzodiazepine More Active than Diazepam*
GASTAUT, H., COURJON, J., POIRE, R., & WEBER, M. (1971) · Epilepsia · doi:10.1111/j.1528-1157.1971.tb04928.x · Cited by 82 · cited 1×
“Since the first clinical publication by Gastaut in 1971 [142], few clinical trials have been conducted to evaluate the efficacy of CZP for SE.”
BackgroundAgarwal, S. K., Kriel, R. L., Brundage, R. C., Ivaturi, V. D., & Cloyd, J. C. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.02.018 · Cited by 81
Talukdar, B., & Chakrabarty, B. (2008) · Brain and Development · doi:10.1016/j.braindev.2008.11.006 · Cited by 81
Rectal Diazepam Gel for Treatment of Acute Repetitive Seizures in Adults
Cereghino, J. J. (2002) · Archives of Neurology · doi:10.1001/archneur.59.12.1915 · Cited by 81
Schubert‐Bast, S., Zöllner, J. P., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Eldar‐Lissai, A., Rosenow, F., & Strzelczyk, A. (2019) · Epilepsia · doi:10.1111/epi.14729 · Cited by 81
Self-citationAshrafi, M. R., Khosroshahi, N., Karimi, P., Malamiri, R. A., Bavarian, B., Zarch, A. V., Mirzaei, M., & Kompani, F. (2010) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2010.05.009 · Cited by 79
Identifying seizure clusters in patients with epilepsy
Haut, S. R., Lipton, R. B., LeValley, A. J., Hall, C. B., & Shinnar, S. (2005) · Neurology · doi:10.1212/01.wnl.0000180685.84547.7f · Cited by 79
Sutter, R., Tschudin‐Sutter, S., Grize, L., Fuhr, P., Bonten, M. J. M., Widmer, A. F., Marsch, S. C. U., & Rüegg, S. J. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03576.x · Cited by 78
Mitchell, W. G., Conry, J. A., Crumrine, P. K., Kriel, R. L., Cereghino, J. J., Groves, L., Rosenfeld, W. E., & North American Diastat Group (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02047.x · Cited by 78
Wermeling, D. P., Record, K. E., Kelly, T. H., Archer, S. M., Clinch, T., & Rudy, A. C. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000226150.90317.16 · Cited by 78
Welch, R. D., Nicholas, K. S., Durkalski‐Mauldin, V. L., Lowenstein, D. H., CONWIT, R. A., Mahajan, P., Lewandowski, C., Silbergleit, R., & the Neurological Emergencies Treatment Trials (NETT) Network Investigators (2015) · Epilepsia · doi:10.1111/epi.12905 · Cited by 75
A Comparison of Buccal Midazolam and Rectal Diazepam for the Acute Treatment of Seizures
Baysun, Ş., Aydın, Ö. F., Atmaca, E., & Gürer, Y. K. Y. (2005) · Clinical Pediatrics · doi:10.1177/000992280504400904 · Cited by 75
Thakker, A., & Shanbag, P. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6659-3 · Cited by 72 · cited 1×
“DZP in prolonged (febrile) seizures in children [15, 82].”
BackgroundPlasma Protein Binding of Diazepam and Tolbutamide in Chronic Alcoholics
Thiessen, J. J., Sellers, E. M., DENBEIGH, P., & Dolman, L. I. (1976) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1976.tb01531.x · Cited by 72 · cited 1×
“However, the half-life and free fraction of DZP increases in aged populations due to reduced carrier albumin serum levels and a high plasma protein binding of > 98% [93, 94].”
BackgroundHogan, R. E., Gidal, B. E., Koplowitz, B., Koplowitz, L. P., Lowenthal, R. E., & Carrazana, E. J. (2020) · Epilepsia · doi:10.1111/epi.16449 · Cited by 72
Rectal diazepam gel for treatment of acute repetitive seizures
Kriel, R. L., Cloyd, J. C., Pellock, J. M., Mitchell, W. G., Cereghino, J. J., & Rosman, N. P. (1999) · Pediatric Neurology · doi:10.1016/s0887-8994(98)00156-8 · Cited by 68
Sreenath, T. G., Gupta, P., Sharma, K. K., & Krishnamurthy, S. (2009) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2009.02.004 · Cited by 68 · cited 2×
“Several severe TEAEs have also been reported, mostly due to respiratory depression that, in some cases, required mechanical ventilation [50, 72, 117, 118, 121].”
BackgroundGreenblatt, D. J., & Sethy, V. H. (1990) · Psychopharmacology · doi:10.1007/bf02244106 · Cited by 68
Home and hospital treatment of acute seizures in children with nasal midazolam
Jeannet, P., Roulet, E., Maeder‐Ingvar, M., Gehri, M., Jutzi, A., & Deonna, T. W. (1999) · European Journal of Paediatric Neurology · doi:10.1016/s1090-3798(99)80016-6 · Cited by 64
Characteristics of large patient‐reported outcomes: Where can one million seizures get us?
Ferastraoaru, V., Goldenholz, D. M., Chiang, S., Moss, R., Theodore, W. H., & Haut, S. R. (2018) · Epilepsia Open · doi:10.1002/epi4.12237 · Cited by 64
Prevalence of acute repetitive seizures (ARS) in the United Kingdom
Martínez, C., Sullivan, T., & Hauser, W. A. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.08.006 · Cited by 63
Guterman, E. L., Betjemann, J. P., Aimetti, A. A., Li, J. W., Wang, Z., Yin, D., Hulihan, J. F., Lyons, T. M., Miyasato, G., & Strzelczyk, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0520 · Cited by 63
Self-citationValproate versus diazepam for generalized convulsive status epilepticus: a pilot study
Chen, W., Gao, R., Su, Y., Zhao, J., Zhang, Y. Z., Wang, L., Ren, Y., & Fan, C. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03420.x · Cited by 62 · cited 1×
“Subsequently, several studies have compared the efficacy of DZP and valproate (VPA) for terminating SE and showed a response rate of 56–85% for DZP and 50–80% for VPA [116, 117].”
BackgroundCrevoisier, C., Delisle, M. C., Joseph, I., & Foletti, G. (2003) · European Neurology · doi:10.1159/000069089 · Cited by 62 · cited 1×
“[151], oral droplets [152] or subcutaneous [153] formulations.”
BackgroundDIAZEPAM RECTAL SOLUTION FOR HOME TREATMENT OF ACUTE SEIZURES IN CHILDREN
HOPPU, K., & SANTAVUORI, P. (1981) · Acta Paediatrica · doi:10.1111/j.1651-2227.1981.tb16565.x · Cited by 62
Nakken, K. O., & Lossius, M. I. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01474.x · Cited by 60 · cited 1×
“With regard to the safety and tolerability of DZP, frequent substance-specific treatment-emergent adverse events (TEAEs) have been identified, including somnolence, sedation, drowsiness, vomiting, hyperactivity, tiredness, hypotension and ataxia [77, 83, 107, 113, 120, 124, 135].”
BackgroundLorazepam therapy of status epilepticus in children and adolescents
Lacey, D. J., Singer, W. D., Horwitz, S. J., & Gilmore, H. E. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)81065-4 · Cited by 60
Gennaro, G. D., Picardi, A., Sparano, A., Mascia, A., Meldolesi, G., Grammaldo, L. G., Esposito, V., & Quarato, P. P. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.08.011 · Cited by 60
Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism
Seree, E., Pisano, P., Placidi, M., Rahmani, R., & Barra, Y. (1993) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1993.tb00219.x · Cited by 59 · cited 1×
“Similarly, CYP inhibitors, such as antifungal agents, may impair CZP metabolism [154, 155].”
BackgroundIntrarectal diazepam in epileptic adults
Remy, C., Jourdil, N., Villemain, D., Favel, P., & Genton, P. (1992) · Epilepsia · doi:10.1111/j.1528-1157.1992.tb02327.x · Cited by 58
Ulvi, H., Yoldaş, T. K., M�ngen, B., & Yiğiter, R. (2002) · Neurological Sciences · doi:10.1007/s100720200058 · Cited by 58
Pharmacokinetics and pharmacodynamics of nasally delivered midazolam
Haschke, M., Suter, K., Hofmann, S., Witschi, R., Fröhlich, J., Imanidis, G., Drewe, J., Briellmann, T. A., Dussy, F. E., Krähenbühl, S., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03611.x · Cited by 56
Mittal, P., Manohar, R., & Rawat, A. (2006) · The Indian Journal of Pediatrics · doi:10.1007/bf02758299 · Cited by 53
Intramuscular midazolam vs intravenous diazepam for acute seizures
Shah, I., & Deshmukh, C. T. (2005) · The Indian Journal of Pediatrics · doi:10.1007/bf02724074 · Cited by 52 · cited 1×
“DZP, respectively [72, 123, 124], and a 94% rate for the r.”
BackgroundBuccal midazolam for treatment of prolonged seizures in children
Kutlu, N. O., Doğrul, M., Yakıncı, C., & Soylu, H. (2003) · Brain and Development · doi:10.1016/s0387-7604(02)00230-9 · Cited by 51
Wheless, J. W., Meng, T., Ess, P. J. V., Detyniecki, K., Sequeira, D. J., & Pullman, W. E. (2019) · Epilepsia · doi:10.1111/epi.16300 · Cited by 51
Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants
French, J. A., Wechsler, R. T., Gelfand, M. A., Pollard, J. R., Vázquez, B., Friedman, D. J., Gong, L. H., Kamemoto, E. S., Isojärvi, J. I. T., & Cassella, J. V. (2019) · Epilepsia · doi:10.1111/epi.16279 · Cited by 50
Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy
Herzog, A. G., & Frye, C. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000623 · Cited by 49 · cited 1×
“, a worsening of seizures in relation to the menstrual cycle) may result in perimenstrual seizure clusters [33, 34].”
BackgroundWermeling, D. P., Record, K. E., Archer, S. M., & Rudy, A. C. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.10.005 · Cited by 49
Lorazepam versus diazepam for the treatment of status epilepticus
Giang, D., & McBride, M. C. (1988) · Pediatric Neurology · doi:10.1016/0887-8994(88)90083-5 · Cited by 49
Intravenous Clonazepam in the Treatment of Status Epilepticus in Children
Congdon, P. J., & Forsythe, W. I. (1980) · Epilepsia · doi:10.1111/j.1528-1157.1980.tb04049.x · Cited by 47 · cited 1×
“75 mg) in all cases without significant side effects [141].”
BackgroundGrosset, K. A., Malek, N., Morgan, F., & Grosset, D. G. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-120142 · Cited by 46 · cited 1×
“New routes of drug administration, such as the intrapulmonary route, are currently being investigated for the treatment of epilepsy and other disorders [162, 163].”
BackgroundKeating, G. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0075-9 · Cited by 46 · cited 1×
“New routes of drug administration, such as the intrapulmonary route, are currently being investigated for the treatment of epilepsy and other disorders [162, 163].”
BackgroundLau, C. E., Ma, F., Wang, Y., & Smith, C. (1996) · Psychopharmacology · doi:10.1007/bf02246454 · Cited by 46
Abou-Khalil, B. W., Wheless, J. W., Rogin, J. B., Wolter, K. D., Pixton, G. C., Shukla, R. B., Sherman, N. A., Sommerville, K. W., Goli, V., & Roland, C. L. (2013) · Epilepsia · doi:10.1111/epi.12373 · Cited by 43
Refractory Status Epilepticus in Children: Role of Continuous Diazepam Infusion
Singhi, S. C., Banerjee, S., & SINGHI, P. D. (1998) · Journal of Child Neurology · doi:10.1177/088307389801300104 · Cited by 43 · cited 1×
“With regard to the safety and tolerability of DZP, frequent substance-specific treatment-emergent adverse events (TEAEs) have been identified, including somnolence, sedation, drowsiness, vomiting, hyperactivity, tiredness, hypotension and ataxia [77, 83, 107, 113, 120, 124, 135].”
BackgroundIntravenous Diazepam in the Treatment of Prolonged Seizure Activity in Neonates and Infants
Smith, B. T., & Masotti, R. E. (1971) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.1971.tb08328.x · Cited by 41
Milligan, N. M., Dhillon, S., Griffiths, A., Oxley, J., & Richens, A. (1984) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.3.235 · Cited by 41
Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers
Ivaturi, V. D., Riss, J., Kriel, R. L., & Cloyd, J. C. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2009.01170.x · Cited by 39
Intravenous Diazepam, Midazolam and Lorazepam in Acute Seizure Control
Gathwala, G., Goel, M., Singh, J., & Mittal, K. (2011) · The Indian Journal of Pediatrics · doi:10.1007/s12098-011-0505-y · Cited by 39
Hardmeier, M., Zimmermann, R., Rüegg, S. J., Pflueger, M. O., Deuster, S., Suter, K., Donzelli, M., Drewe, J., Krähenbühl, S., Fuhr, P., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.316 · Cited by 39 · cited 1×
“MDZ reaches dose-dependent maximal plasma concentrations after ~ 8–14 min, with sneezing and local irritation reported as the most common side effects [58, 78].”
BackgroundWassmer, E., Qureshi, A. M., Davies, P. A., Berry, K., & Whitehouse, W. P. (2002) · Seizure · doi:10.1053/seiz.2001.0635 · Cited by 38
Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus
Chamberlain, J. M., Capparelli, E. V., Brown, K. M., Vance, C., Lillis, K., Mahajan, P., Lichenstein, R., Stanley, R. M., Davis, C. O., Gordon, S. B., et al. (2011) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.09.048 · Cited by 38
Use of Emergency Medication in Adult Patients with Epilepsy: A Multicentre Cohort Study from Germany
Kadel, J., Bauer, S., Hermsen, A., Immisch, I., Kay, L., Klein, K. M., Knake, S., Menzler, K., Reif, P. S., Rosenow, F., et al. (2018) · CNS Drugs · doi:10.1007/s40263-018-0544-2 · Cited by 38
Self-citationTHE USE OF CLONAZEPAM AS AN ANTICONVULSANT—CLINICAL EVALUATION
BLADIN, P. F. (1973) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1973.tb110623.x · Cited by 38
Treatments for seizures in catamenial (menstrual-related) epilepsy
Maguire, M., & Nevitt, S. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013225.pub2 · Cited by 38
Kay, L., Merkel, N. B., von Blomberg, A., Willems, L. M., Bauer, S., Reif, P. S., Schubert‐Bast, S., Rosenow, F., & Strzelczyk, A. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50932 · Cited by 38 · cited 2×
“administration could already be measured after 4 min, which preceded the clinical end of the seizure by ~ 1 min [66].”
BackgroundMethodSelf-citationGizurarson, S. S., Guðbrandsson, F. K., Jónsson, H., & Bechgaard, E. (1999) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.22.425 · Cited by 37
Kay, L., Reif, P. S., Belke, M., Bauer, S., Fründ, D., Knake, S., Rosenow, F., & Strzelczyk, A. (2015) · Epilepsia · doi:10.1111/epi.13088 · Cited by 36
Self-citationDissolving Oral Clonazepam Wafers in the Acute Treatment of Prolonged Seizures
Troester, M. M., Hastriter, E. V., & Ng, Y. (2010) · Journal of Child Neurology · doi:10.1177/0883073810368312 · Cited by 35 · cited 2×
“formulations, a retrospective study investigating the efficacy of CZP wafers for the acute treatment of prolonged seizures in children and young adults (2–25 years) reported seizure termination in 38/56 (68%) patients [148].”
BackgroundAcharya, S., Adamová, D., Adler, A., Adolfsson, J., Rinella, G. A., Agnello, M., Agrawal, N., Ahammed, Z., Ahmad, S., Ahn, S. U., et al. (2021) · Physical Review Letters · doi:10.1103/physrevlett.127.272001 · Cited by 35
Comparative trial of intravenous lorazepam and clonazepam im status epilepticus.
Sorel, L., Mechler, L., & Harmant, J. (1981) · PubMed · Cited by 34
Lamson, M. J., Sitki‐Green, D., Wannarka, G. L., Mesa, M., Andrews, P. A., & Pellock, J. M. (2011) · Clinical Drug Investigation · doi:10.2165/11590250-000000000-00000 · Cited by 34
Garnock-Jones, K. P. (2012) · Pediatric Drugs · doi:10.2165/11209320-000000000-00000 · Cited by 34
Acharya, S., Adamová, D., Adler, A., Adolfsson, J., Rinella, G. A., Agnello, M., Agrawal, N., Ahammed, Z., Ahmad, S., Ahn, S. U., et al. (2021) · Physical Review Letters · doi:10.15120/gsi-2022-00078 · Cited by 34
Kaputu-Kalala-Malu, C., Kahamba, D. M., Walker, T. D., Mukampunga, C., Musalu, É. M., Kokolomani, J., Mayamba, R. M. K., Wilmshurst, J. M., Dubru, J.-M., & Misson, J. (2013) · Journal of Child Neurology · doi:10.1177/0883073813493501 · Cited by 33
Treatment and course of different subtypes of status epilepticus
Rantsch, K., Walter, U., Wittstock, M., Benecke, R., & Rösche, J. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2013.08.001 · Cited by 33 · cited 21×
“Interestingly, only 85% of the patients received BZDs as a first-line treatment and 59% were prescribed an insufficient dosage [53].”
BackgroundInfluentialJavadzadeh, M., Sheibani, K., Hashemieh, M., & Saneifard, H. (2012) · PubMed · Cited by 33
Henney, H. R., Sperling, M. R., Rabinowicz, A. L., Bream, G., & Carrazana, E. J. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.04.007 · Cited by 33
Treatment of Acute Seizures: Is Intranasal Midazolam a Viable Option?
Humphries, L. K., & Eiland, L. S. (2013) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-18.2.79 · Cited by 32 · cited 1×
“Benzodiazepines (BZDs), such as lorazepam (LZP), midazolam (MDZ), diazepam (DZP) and clonazepam (CZP), are established first-line drugs for the acute treatment of seizures [5].”
BackgroundNew Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective
Mula, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0398-4 · Cited by 32 · cited 2×
“Fortunately, several delivery routes for BZDs have now been established, which are suitable for both lay users and medical staff [9].”
BackgroundSemmlack, S., Tschudin‐Sutter, S., Widmer, A. F., Valença, M. F., Rüegg, S. J., Marsch, S. C. U., & Sutter, R. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8140-1 · Cited by 31
Momen, A. A., Malamiri, R. A., Nikkhah, A., Jafari, M. T., Fayezi, A., Riahi, K., & Maraghi, E. (2014) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2014.11.007 · Cited by 30 · cited 1×
“DZP [74] in terminating motor activity during SE in children, and that fewer children receiving i.”
BackgroundBioavailability and tolerability of intranasal diazepam in healthy adult volunteers
Ivaturi, V. D., Riss, J., Kriel, R. L., Siegel, R. A., & Cloyd, J. C. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.01.001 · Cited by 30
Preliminary study of parenteral lorazepam in status epilepticus.
Waltregny, A., & Dargent, J. (1975) · PubMed · Cited by 30
The pharmacology of alprazolam: a review.
Huybrechts, I. (1991) · PubMed · Cited by 29
Garnett, W. R., Barr, W. H., Edinboro, L. E., Karnes, H. T., Mesa, M., & Wannarka, G. L. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.10.001 · Cited by 29
von Blomberg, A., Kay, L., Knake, S., Fuest, S., Zöllner, J. P., Reif, P. S., Herrmann, E. M., Balaban, Ü., Schubert‐Bast, S., Rosenow, F., et al. (2020) · CNS Drugs · doi:10.1007/s40263-020-00720-w · Cited by 29
Self-citationMartin, D., & Hirt, H. R. (1973) · Neuropediatrics · doi:10.1055/s-0028-1091744 · Cited by 28
Portela, J. D. L., Garcia, P. C. R., Piva, J. P., Barcelos, A., Bruno, F., Branco, R. G., & Tasker, R. C. (2014) · Medicina Intensiva · doi:10.1016/j.medin.2014.04.003 · Cited by 28
Dosing feasibility and tolerability of intranasal diazepam in adults with epilepsy
Sperling, M. R., Haas, K. F., Krauss, G. L., Eddeine, H. S., Henney, H. R., Rabinowicz, A. L., Bream, G., Squillacote, D., & Carrazana, E. J. (2014) · Epilepsia · doi:10.1111/epi.12755 · Cited by 28
Status epilepticus - time is brain and treatment considerations
Der-Nigoghossian, C. A., Rubiños, C., Alkhachroum, A. M., & Claassen, J. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000661 · Cited by 28 · cited 1×
“As it has been shown that interrupting SE as soon as possible reduces the chance of developing RSE and improves outcomes, ensuring rapid treatment in acute care is at least as important, if not more important, than the BZD choice [182].”
BackgroundTreatment of seizures and epilepsy in children and adolescents
Pellock, J. M. (1998) · Neurology · doi:10.1212/wnl.51.5_suppl_4.s8 · Cited by 27
Different as night and day: Patterns of isolated seizures, clusters, and status epilepticus
Goldenholz, D. M., Rakesh, K., Kapur, K., Gaínza‐Lein, M., Hodgeman, R. M., Moss, R., Theodore, W. H., & Loddenkemper, T. (2018) · Epilepsia · doi:10.1111/epi.14076 · Cited by 25 · cited 1×
“A better understanding of the prediction, occurrence and clustering of seizures will likely result from big data approaches, which may help to better define the clinical course and dynamics of seizure clusters [35, 36].”
BackgroundAbdel-Bar, H. M., Abdel-Reheem, A. Y., Awad, G. A. S., & Mortada, N. D. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j30s31 · Cited by 24 · cited 1×
“CZP administration using nanocarriers was demonstrated to be safe and effective [149], and oral droplet administration (with CZP dissolved into droplets of propylene glycol) has been shown to achieve therapeutic levels within 10–15 min [152].”
Plasma concentrations of clonazepam after single rectal administration.
Rylance, G., Poulton, J., Cherry, R. C., & Cullen, R. (1986) · Archives of Disease in Childhood · doi:10.1136/adc.61.2.186 · Cited by 24 · cited 1×
“1 mg/kg) showed plasma concentrations indicating a rapid absorption (Tmax 10 min–2 h, mean 30 min) [150].”
BackgroundWillems, L. M., Bauer, S., Jahnke, K., Voß, M., Rosenow, F., & Strzelczyk, A. (2020) · CNS Drugs · doi:10.1007/s40263-020-00747-z · Cited by 24 · cited 4×
“Even if not designed to evaluate CZP efficacy, a randomized double-blind trial (SAMUKeppra) evaluating i.v. levetiracetam (LEV; 2.5 g) plus i.v. CZP (1 mg) versusplacebo plus i.v. CZP in outpatient GCSE treatment offered good insights regarding CZP efficacy [143].”
BackgroundInfluentialSelf-citationRogin, J. B., Wheless, J. W., Abou-Khalil, B. W., Wolter, K. D., Pixton, G. C., Sherman, N. A., Shukla, R. B., Roland, C. L., & Sommerville, K. W. (2014) · Epilepsia · doi:10.1111/epi.12685 · Cited by 23
A Comparison of Intraosseous and Intravenous Routes of Administration for Antiseizure Agents
Lathers, C. M., Jim, K. F., & Spivey, W. H. (1989) · Epilepsia · doi:10.1111/j.1528-1157.1989.tb05328.x · Cited by 23
Lorazepam in therapy for status epilepticus
Griffith, P. A., & Karp, H. R. (1980) · Annals of Neurology · doi:10.1002/ana.410070521 · Cited by 22
Treatment of status epilepticus with intravenous clonazepam
Singh, A. N., & Morvan, P. L. (1982) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(82)80146-2 · Cited by 22
Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant.
Hooper, W. D., DICKINSON, R. G., Dunstan, P. R., Pendlebury, S. C., & Eadie, M. J. (1987) · PubMed · Cited by 21
Clonazepam in the treatment of status epilepticus
Shangguan, Y., Liao, H., & Wang, X. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1056781 · Cited by 20 · cited 1×
“administration of CZP in SE care is still a additional alternative [185].”
BackgroundNeligan, A., Noyce, A. J., Gosavi, T., Shorvon, S. D., Köhler, S., & Walker, M. C. (2019) · UCL Discovery (University College London) · Cited by 20
The effects of benzodiazepines in pregnancy.
Leppée, M., Čulig, J., Erić, M., & Šijanović, S. (2010) · PubMed · Cited by 19
Nasal and Buccal Treatment of Midazolam in Epileptic Seizures in Pediatrics
Ülgey, A., Aksu, R., & Biçer, C. (2012) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8330 · Cited by 17 · cited 1×
“This drug is primarily metabolized in the liver by cytochrome P450 3A4 (CYP3A4), and its metabolites, mainly 1-hydroxymidazolam, are excreted in the urine [63].”
BackgroundSeizure Protection by Intrapulmonary Delivery of Propofol Hemisuccinate
Dhir, A., Żółkowska, D., Murphy, R. B., & Rogawski, M. A. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173591 · Cited by 17 · cited 1×
“Dhir and colleagues also showed that MDZ and a propofol prodrug are highly effective antiseizure drugs when administered intrapulmonarily in a preclinical model [166, 167].”
BackgroundOwusu, K. A., Dhakar, M. B., Bautista, C. A., McKimmy, D., Cotugno, S., Sukumar, N., Deng, Y., Farooque, P., Hirsch, L. J., & Maciel, C. B. (2019) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2019.07.021 · Cited by 17 · cited 1×
“LZP for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit [84].”
BackgroundGreenblatt, D. J., Blaskovich, P., Nuwayser, E. S., Harmatz, J. S., Chen, G., & Zinny, M. A. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280861 · Cited by 16 · cited 2×
“Subcutaneous injection of CZP (microspheres) demonstrated complete absorption with a slow-release pharmacokinetic profile [153].”
BackgroundTonekaboni, S. H., Shamsabadi, F. M., Anvari, S.-S., Mazrooei, A., & Ghofrani, M. (2012) · Europe PMC (PubMed Central) · Cited by 16
Benzodiazepine Selection in the Management of Status Epilepticus: A Review
Rogalski, R., & Rogalski, A. (2015) · Advanced Emergency Nursing Journal · doi:10.1097/tme.0000000000000064 · Cited by 15 · cited 1×
“Over the last several decades, different BZDs have been established as first-line therapies for SE, each of which has its own pharmacological characteristics with advantages and disadvantages [180].”
BackgroundPoukas, V. S., Pollard, J. R., & Anderson, C. T. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0207-x · Cited by 13 · cited 1×
“The delineation between prolonged epileptic seizures, seizure clusters and SE is—to some extent—arbitrary and has evolved over the last few decades; however, any rescue medication should prevent seizure recurrence as well as the progression of a seizure or a series of seizures into SE [1, 4].”
BackgroundFakhoury, T. A., Chumley, A., & Bensalem‐Owen, M. (2007) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2007.05.014 · Cited by 12
Clonazepam Oral Droplets for the Treatment of Acute Epileptic Seizures
Sakata, O., Onishi, H., & Machida, Y. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040802122977 · Cited by 12 · cited 2×
“[151], oral droplets [152] or subcutaneous [153] formulations.”
BackgroundRapid Arrest of Seizures with an Inhalation Aerosol Containing Diazepam
Liu, X., Zheng, W. M., Zhen, S., & Xian, N. S. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02444.x · Cited by 11 · cited 1×
“treated 120 patients with seizures in a single-blind trial with inhalable DZP and showed a significant effect on seizure control [165].”
Greenblatt, D. J., Divoll, M., Harmatz, J. S., Shader, R. I., & Wyant, G. M. (1983) · Survey of Anesthesiology · doi:10.1097/00132586-198310000-00013 · Cited by 10
Seizure protection by intrapulmonary delivery of midazolam in mice
Dhir, A., Żółkowska, D., & Rogawski, M. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.002 · Cited by 10 · cited 1×
“Dhir and colleagues also showed that MDZ and a propofol prodrug are highly effective antiseizure drugs when administered intrapulmonarily in a preclinical model [166, 167].”
BackgroundGonzález, D., Chamberlain, J. M., Guptill, J. T., Cohen‐Wolkowiez, M., Harper, B., Zhao, J. M., & Capparelli, E. V. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0486-0 · Cited by 10 · cited 1×
“1 mg/kg, to a maximum of 4 mg) can be used to achieve serum concentrations of 50–100 ng/ml in children with SE, which have been previously associated with effective seizure control [175, 176].”
MethodChamberlain, D. B., & Chamberlain, J. M. (2016) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2016.08.449 · Cited by 10
[Pharmacokinetic of benzodiazepines in old age].
Vožeh, S. (1981) · PubMed · Cited by 9
Is Intranasal Midazolam Better Than Rectal Diazepam for Home Management of Acute Seizures?
Sirsi, D. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.337 · Cited by 8
ACUTE TREATMENT OF EPILEPTIC SEIZURES WITH DIAZEPAMUM (VALIUM®)
Henriksen, P. B. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1967.tb02102.x · Cited by 7
Ketz, E., Bernoulli, C., & Siegfried, J. (1973) · PubMed · Cited by 6
Initiale Therapie des Status epilepticus: Welche Therapie erfolgt zu Hause und im Rettungswagen?
Möddel, G., Kellinghaus, C., & Strzelczyk, A. (2018) · Clinical Epileptology · doi:10.1007/s10309-018-0204-z · Cited by 6
Self-citationA comparison of intravenous midazolam and diazepam in management of status epilepticus in children
Kazmi, A., Abbas, G., Khurshid, A., Shah, S., Mallhi, T. H., Hanif, M. A., Saleem, U., Shah, A. M., Riaz, N., & Admin (2020) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.843 · Cited by 6
DRUG INTERACTIONS WITH DIAZEPAM
Bojanić, Z., Bojanic, N. Z., Bojanić, V., & Lazović, M. (2011) · Acta Medica Medianae · doi:10.5633/amm.2011.0214 · Cited by 5 · cited 1×
“In addition, oral contraceptives can inhibit the biotransformation of DZP, thereby increasing its effects and possibly increasing the incidence of break-through bleeding [87].”
BackgroundTrajano, M. L. M., Sanchez, B., Lukban, M., & Salonga, A. M. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70969-4 · Cited by 4
[Clinical use and effect of Ro 5-4023 (clonazepam) in different forms of epileptic seizures].
Kruse, R., & Blankenhorn (1973) · PubMed · Cited by 4
[A control study on the treatment of acute seizures with midazolam and diazepam in children].
Tang, R.-H., & Zhou, J.-B. (2010) · PubMed · Cited by 3
Transnasal Revolution? The Promise of Midazolam Spray to Prevent Seizure Clusters
Sutter, R., & Kaplan, P. W. (2020) · CNS Drugs · doi:10.1007/s40263-020-00724-6 · Cited by 3 · cited 1×
“MDZ can reduce the transformation of seizures into a status epilepticus, the number of applications without increasing adverse events, and whether the availability of MDZ spray increases the rate of BZD administrations by emergency medical services [85].”
BackgroundMidazolam intramuscular en el tratamiento inicial del estado epiléptico
Contreras, D. G., Poblete, E. C., Olivares, L. A., Oyarzo, L. F., & Galdames-Poblete, D. (2006) · Revista de Neurología · doi:10.33588/rn.4206.2004365 · Cited by 2
Research works printed but not linked: 9
- Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weimar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012.
- Singhi S, Murthy A, Singhi P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106–10. · DOI · Paper page
- Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83–6. · DOI · Paper page
- Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253–5. · DOI · Paper page
- Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Dev. 2003;25(4):275–8. · DOI
- Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–808. · DOI · Paper page
- Bergamini L, Mutani R, Fariello R, Liboni W, Quattrocolo GL. Action du Ro 5 ⁄ 4023 dans le traitement des differentes formes d epilepsie. Paper given at the Rivotril Symposium, Marseilles, France. 1972.
- Bergamini L, Mutani R, Liboni W. Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 5 ⁄ 4023. EEG EMG. 1970;1:182–8.
- Tridon P, Weber M. Conduite du traitement des etats de mal epileptiques par le Ro. Sem Hop Paris. 1973;49:29.
Cited by
Developmental and epileptic encephalopathies
Scheffer, I. E., Zuberi, S., Mefford, H. C., Guerrini, R., & McTague, A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00546-6 · Cited by 158
“Acquired structural aetiologies include:”
Diagnosis and management of status epilepticus: improving the status quo
Gettings, J. V., Chafjiri, F. M. A., Patel, A. A., Shorvon, S. D., Goodkin, H. P., & Loddenkemper, T. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00430-7 · Cited by 83
Rossetti, A. O., Claassen, J., & Gaspard, N. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07263-w · Cited by 78
Chowdhury, R., Bhuia, M. S., Hasan, M. S. A., Ansari, S. A., Ansari, I. A., Gurgel, A. P. A. D., Coutinho, H. D. M., & Islam, M. T. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105704 · Cited by 49
Established and emerging GABAA receptor pharmacotherapy for epilepsy
Richardson, R. J., Petrou, S., & Bryson, A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1341472 · Cited by 48
Metadata
- Authors
- Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., Schubert-Bast, S., Rosenow, F., Strzelczyk, A., & Willems, L. M.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Strzelczyk, Adam
- ORCID
- Venue
- CNS Drugs
- Published
- 2022-08-16
- Volume
- 36
- Issue
- 9
- Pages
- 951-975
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC9477921
- OpenAlex
- W4291824793
- Cited by
- 139
- References
- 191
- Citations by year
- 2026: 33 · 2025: 42 · 2024: 37 · 2023: 24 · 2022: 3
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by-nc)
- IRIS (submittedVersion, cc-by-nc)
- SERVAL (Université de Lausanne) (submittedVersion, cc-by-nc)
- Funders
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Sedative Agents
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- benzodiazepines, status epilepticus, prolonged seizures, route of administration, intranasal administration, intrapulmonary administration, clonazepam, diazepam, lorazepam, midazolam, GABAA receptor, pharmacokinetics, pharmacodynamics, efficacy, tolerability, anticonvulsant therapy
- MeSH terms
- Anticonvulsants, Benzodiazepines, Clonazepam, Diazepam, gamma-Aminobutyric Acid, Humans, Lorazepam, Midazolam, Seizures, Status Epilepticus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.